Various studies have been conducted on the duration and efficacy of oxaliplatin-based adjuvant chemotherapy for high-risk stage II and III colon cancer, as well as the impact of KRAS mutations on disease-free survival in BRAF-wild-type stage III colon cancer. These studies provide valuable insights into the optimal treatment strategies for colon cancer patients.